Retained viscoelastic can cause reticular interface haze

Article

Retained viscoelastic at the graft-host interface during DSEK may cause a reticular interface haze that can compromise visual clarity.

Retained viscoelastic at the graft-host interface during DSEK may cause a reticular interface haze that can compromise visual clarity, claims a paper in Retina.

A group led by Dr A. Anshu, Cornea Research Foundation of America, Indianapolis, Indiana, USA, studied five patients who underwent uncomplicated combined DSAEK/phacoemulsification with IOL implantation at a tertiary referral centre over a period of three months.

Each eye had the Descemet membrane stripped and the anterior chamber filled cohesive viscoelastic. As a result, patients developed visually significant haze in the graft-host interface. There was also a small separation between the donor and the recipient cornea in three of the fives cases.

In all patients there was no communication between the area of detachment and the anterior chamber. Patients either went under observation or had surgery to irrigate the viscoelastic from the interface.

Three patients were observed with eventual clearing of the haze and attainment of best-corrected visual acuity of 20/40 or better. The remaining two patients had more extensive haze and visible space on the slit lamp examination and underwent irrigation and aspiration of the graft-host interface. At the last follow-up all grafts were clear.

The abstract can be found here.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.